{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:35:55Z","timestamp":1791430555968,"version":"4.3.3"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis Supplements"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.atherosclerosissup.2015.02.040","type":"journal-article","created":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T05:31:25Z","timestamp":1430458285000},"page":"268-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["The incidence of cardiovascular events is largely reduced in patients with\u00a0maximally tolerated drug therapy and lipoprotein apheresis. A\u00a0single-center experience"],"prefix":"10.1016","volume":"18","author":[{"given":"T.","family":"Sampietro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Sbrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bigazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ripoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Dal Pino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Pasanisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Coceani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pianelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.atherosclerosissup.2015.02.040_bib1","first-page":"1377","article-title":"Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis as heroic treatment","volume":"118","author":"de Gennes","year":"1967","journal-title":"Bull Mem Soc Med Hop Paris"},{"issue":"2","key":"10.1016\/j.atherosclerosissup.2015.02.040_bib2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.atherosclerosis.2009.06.010","article-title":"Efficacy criteria and cholesterol targets for LDL apheresis","volume":"208","author":"Thompson","year":"2010","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.atherosclerosissup.2015.02.040_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/jca.21276","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue","volume":"28","author":"Schwartz","year":"2013","journal-title":"J Clin Apher"},{"issue":"Suppl. 1","key":"10.1016\/j.atherosclerosissup.2015.02.040_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11789-012-0046-6","article-title":"Current view: indications for extracorporeal lipid apheresis treatment","volume":"7","author":"Schettler","year":"2012","journal-title":"Clin Res Cardiol Suppl"},{"issue":"24","key":"10.1016\/j.atherosclerosissup.2015.02.040_bib5","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Lipoprotein apheresis in patients with maximally tolerated lipid lowering therapy, Lp(a)-hyperlipoproteinemia and Progressive cardiovascular disease: prospective observational multicenter study","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.atherosclerosissup.2015.02.040_bib6","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0002-9149(98)00692-4","article-title":"Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group","volume":"82","author":"Mabuchi","year":"1998","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.atherosclerosissup.2015.02.040_bib7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/aor.12135","article-title":"Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?","volume":"38","author":"Rosada","year":"2014","journal-title":"Artif Organs"},{"key":"10.1016\/j.atherosclerosissup.2015.02.040_bib8","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosissup.2015.02.040_bib9","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1161\/01.CIR.96.4.1360","article-title":"Lipid lowering versus revascularization: an idea whose time (for testing) has come","volume":"96","author":"Forrester","year":"1997","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.atherosclerosissup.2015.02.040_bib10","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/CIRCULATIONAHA.107.753152","article-title":"Evidence mandating earlier and more aggressive treatment of hypercholesterolemia","volume":"118","author":"Steinberg","year":"2008","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.atherosclerosissup.2015.02.040_bib11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/11594970-000000000-00000","article-title":"Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia","volume":"11","author":"Lee","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"issue":"6","key":"10.1016\/j.atherosclerosissup.2015.02.040_bib12","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2217\/clp.13.68","article-title":"Lipoprotein apheresis: an update","volume":"8","author":"Julius","year":"2013","journal-title":"Clin Lipidol"},{"issue":"6","key":"10.1016\/j.atherosclerosissup.2015.02.040_bib13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/MOL.0b013e32833e13fd","article-title":"Lipoprotein apheresis","volume":"21","author":"Thompson","year":"2010","journal-title":"Curr Opin Lipidol"},{"issue":"2","key":"10.1016\/j.atherosclerosissup.2015.02.040_bib14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1744-9987.2009.00747.x","article-title":"Retrospective analysis of long-term lipid apheresis at a single center","volume":"14","author":"Koziolek","year":"2010","journal-title":"Ther Apher Dial"},{"issue":"1","key":"10.1016\/j.atherosclerosissup.2015.02.040_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosissup.2012.10.005","article-title":"Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern","volume":"14","author":"von Dryander","year":"2013","journal-title":"Atheroscler Suppl"},{"issue":"23","key":"10.1016\/j.atherosclerosissup.2015.02.040_bib16","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.atherosclerosissup.2015.02.040_bib17","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/heartjnl-2013-304902","article-title":"Lipoprotein(a): the underestimated cardiovascular risk factor","volume":"100","author":"Thompson","year":"2014","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.atherosclerosissup.2015.02.040_bib18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1744-9987.2007.00449.x","article-title":"Apheresis in coronary heart disease with elevated Lp(a): a review of Lp(a) as a risk factor and its management","volume":"11","author":"Keller","year":"2007","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.atherosclerosissup.2015.02.040_bib19","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/0735-1097(92)90520-W","article-title":"Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein(a) abnormalities in men with premature coronary artery disease","volume":"19","author":"Genest","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosissup.2015.02.040_bib20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199907083410202","article-title":"Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"}],"container-title":["Atherosclerosis Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568815000410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568815000410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T01:55:40Z","timestamp":1537667740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567568815000410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":20,"alternative-id":["S1567568815000410"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2015.02.040","relation":{},"ISSN":["1567-5688"],"issn-type":[{"value":"1567-5688","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The incidence of cardiovascular events is largely reduced in patients with\u00a0maximally tolerated drug therapy and lipoprotein apheresis. A\u00a0single-center experience","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis Supplements","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2015.02.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}